This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ho, S. Y.
Right arrow Articles by Alonso, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ho, S. Y.
Right arrow Articles by Alonso, S.

 Previous Article  |  Next Article 

Infection and Immunity, January 2008, p. 111-119, Vol. 76, No. 1
0019-9567/08/$08.00+0     doi:10.1128/IAI.00795-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Highly Attenuated Bordetella pertussis Strain BPZE1 as a Potential Live Vehicle for Delivery of Heterologous Vaccine Candidates{triangledown}

Si Ying Ho,1,2,{dagger} Shi Qian Chua,1,2,{dagger} Damian G. W. Foo,2 Camille Locht,3,4 Vincent T. Chow,2 Chit Laa Poh,2 and Sylvie Alonso1,2*

Immunology Programme,1 Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, 28 Medical Drive, CeLS #03-06N, Singapore 117456, Singapore,2 INSERM, U629,3 Institut Pasteur de Lille, 1 rue du Prof. Calmette, F-59019 Lille, France4

Received 11 June 2007/ Returned for modification 4 October 2007/ Accepted 10 October 2007

Bordetella pertussis, the causative agent of whooping cough, is a promising and attractive candidate for vaccine delivery via the nasal route, provided that suitable attenuation of this pathogen has been obtained. Recently, the highly attenuated B. pertussis BPZE1 strain has been described as a potential live pertussis vaccine for humans. We investigated here the use of BPZE1 as a live vehicle for heterologous vaccine candidates. Previous studies have reported the filamentous hemagglutinin (FHA), a major B. pertussis adhesin, as a carrier to express foreign antigens in B. pertussis. In this study, we also examined the BrkA autotransporter as a surface display system. Three copies of the neutralizing peptide SP70 from enterovirus 71 (EV71) were fused to FHA or in the passenger domain of BrkA, and each chimera was expressed in BPZE1. The FHA-(SP70)3 and BrkA-(SP70)3 chimeras were successfully secreted and exposed at the bacterial surface, respectively. Nasal administration of the live recombinant strains triggered a strong and sustained systemic anti-SP70 antibody response in mice, although the titers and neutralizing activities against EV71 were significantly higher in the sera of mice immunized with the BrkA-(SP70)3-producing strain. These data indicate that the highly attenuated BPZE1 strain is a potential candidate for vaccine delivery via the nasal route with the BrkA autotransporter as an alternative to FHA for the presentation of the heterologous vaccine antigens.

* Corresponding author. Mailing address: Immunology Programme and Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, 28 Medical Drive, CeLS #03-06N, Singapore 117456, Singapore. Phone: (65) 6516-3541. Fax: (65) 6778-2684. E-mail: micas{at}nus.edu.sg

{triangledown} Published ahead of print on 22 October 2007.

Editor: A. Camilli

{dagger} S.Y.H. and S.Q.C. contributed equally to this work.

Infection and Immunity, January 2008, p. 111-119, Vol. 76, No. 1
0019-9567/08/$08.00+0     doi:10.1128/IAI.00795-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»